# Delcath Systems, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Delcath Systems, Inc).

## Overview

Delcath Systems is a U.S.-based interventional oncology company focused on treating cancers that are primary to, or have spread to, the liver. Its core commercial product is HEPZATO KIT, a drug/device combination therapy approved for adult patients with unresectable hepatic metastases from uveal melanoma, and the company also markets CHEMOSAT in Europe.

## Products & services

• HEPZATO KIT (melphalan for Injection/Hepatic Delivery System)
• CHEMOSAT Hepatic Delivery System
• Interventional oncology treatment for liver-dominant cancers
• Clinical development of HEPZATO in additional indications
• Commercial support, marketing, and distribution services

- **Commercial oncology products** (80%) — Approved liver-directed therapies sold for use in eligible cancer patients.
- **European CHEMOSAT system** (15%) — CHEMOSAT-based treatment used in Europe for hepatic-dominant cancer care.
- **Clinical development programs** (5%) — Research and trials aimed at expanding HEPZATO into additional indications.

- HEPZATO KIT for liver-directed treatment of metastatic uveal melanoma
- CHEMOSAT hepatic delivery system for European markets
- Drug/device combination therapy for liver-dominant cancers
- Clinical development of HEPZATO in mCRC and mBC
- Commercialization, marketing, and physician education support

## Customers

Delcath sells primarily to hospitals, cancer centers, and interventional oncology facilities that treat patients with liver-dominant metastatic disease. Demand is driven by specialist physicians and treatment centers that can perform the procedure and manage complex oncology patients. In the U.S., commercialization depends on physician adoption and facility access, while in Europe the customer base includes centers using CHEMOSAT under local market and reimbursement conditions.

- **U.S. oncology treatment centers** (primary) — Buy and use HEPZATO KIT for eligible adult patients with unresectable hepatic metastases from uveal melanoma.
- **European interventional oncology centers** (primary) — Use CHEMOSAT for liver-directed cancer treatment in markets where the system is commercialized.
- **Physician referral network** (secondary) — Oncologists and interventional radiologists refer patients and drive adoption by educating eligible patients.
- **Clinical trial sites** (emerging) — Participate in studies for new indications such as mCRC and mBC to expand future use cases.

- Hospitals and cancer centers treating uveal melanoma with liver metastases
- Interventional oncology facilities that can perform the HEPZATO procedure
- European treatment centers using CHEMOSAT for hepatic-dominant cancers
- Physicians who need a liver-directed option for hard-to-treat patients
- Covered entities and payors that influence access and pricing

## Geography

Delcath is headquartered in Queensbury, New York and commercializes HEPZATO in the United States while also selling CHEMOSAT in Europe. The company’s growth is tied to U.S. physician adoption and reimbursement, but its European presence adds exposure to different healthcare systems, pricing rules, and regulatory requirements. Manufacturing and outsourced support activities are not fully detailed in the excerpts, but the business relies on consultants and third parties for marketing, quality, manufacturing, and corporate services.

- Headquartered in Queensbury, New York, United States
- U.S. commercialization is centered on HEPZATO adoption
- Europe is the main market for CHEMOSAT sales
- Revenue depends on healthcare access and reimbursement by region
- Uses third parties and consultants for manufacturing and support

## Strategy

Delcath’s strategy is to build HEPZATO into a durable commercial franchise in the U.S. while sustaining CHEMOSAT demand in Europe. The company is also investing in clinical expansion, including trials in metastatic colorectal cancer and breast cancer, to broaden the addressable market beyond uveal melanoma. Commercial execution, physician education, and reimbursement access are central to turning the approved product into repeatable sales.

- **Grow U.S. commercial adoption of HEPZATO** (short-term) — The product is approved and first commercial use began in 2024, so scaling utilization is the main near-term value driver.
- **Expand clinical pipeline beyond uveal melanoma** (medium-term) — Additional indications could materially enlarge the market and reduce dependence on a single rare-cancer franchise.
- **Sustain European CHEMOSAT commercialization** (medium-term) — Europe provides a second commercial channel and diversifies the company’s revenue base.

- Expand U.S. HEPZATO adoption through physician education and site growth
- Maintain and grow CHEMOSAT commercialization in Europe
- Advance clinical trials in mCRC and mBC to widen indications
- Strengthen sales and marketing capabilities for specialty oncology markets
- Preserve liquidity to fund commercialization and development

## Risks

Delcath remains exposed to commercialization risk because HEPZATO is a newly launched specialty product and adoption depends on physician access, reimbursement, and treatment-center capacity. The business also faces regulatory, intellectual property, and cybersecurity risks, while its small scale makes it sensitive to execution missteps, clinical trial outcomes, and cash burn. Because the company relies on third parties for parts of its operating model, supply-chain and vendor performance are also important.

- **Commercial adoption risk for HEPZATO** [high] — Revenue depends on a limited number of specialist centers and physician uptake of a new therapy.
- **Reimbursement and pricing pressure** [high] — Healthcare consolidation and payor rules can force discounts or restrict utilization.
- **Clinical development failure** [high] — Future growth depends on successful trials in mCRC and mBC and other indications.
- **Intellectual property protection** [medium] — Weak patent or trade secret protection could allow competitors to copy the technology.
- **Cybersecurity and third-party dependency** [medium] — The company relies on consultants and external systems, increasing operational vulnerability.

- HEPZATO adoption may be slower than expected in a niche oncology market
- Reimbursement and pricing pressure can limit access and margins
- Clinical trials may fail to expand the product into new indications
- IP protection may be insufficient against competitors
- Cybersecurity and third-party vendor risks can disrupt operations

## Accounting

The most important accounting issues are revenue recognition for a newly commercialized drug/device product, valuation of warrants and other equity-linked instruments, and estimates tied to stock-based compensation and clinical development costs. Because the company is still scaling, quarter-to-quarter results can move materially with product demand, launch timing, and the mix of commercial versus development spending. Investors should also watch fair value measurements, short-term investments, and any impairment or contingent liability judgments as the business evolves.

- **Revenue recognition and net pricing adjustments** — Net revenue can differ materially from gross product sales.
- **Fair value of warrants and equity-linked instruments** — Non-cash gains or losses may create volatility in other income/expense.
- **Stock-based compensation** — Raises operating expense and can materially affect reported losses.
- **Clinical development cost capitalization versus expense** — R&D expense can swing with trial initiation and headcount changes.

- Revenue recognition depends on product shipment, pricing, rebates, and payor programs
- 340B, Medicaid, and VA pricing can affect net revenue realization
- Stock-based compensation is meaningful due to employee and option grants
- Warrant valuation and exercises can affect equity and other income
- Clinical trial and commercialization costs create period-to-period volatility

---

*Last updated: 2026-09-24T11:47:40.963328+00:00*